163 completed, 53 unknown, 24 terminated, 11 recruiting. 53 Phase 3, 51 Phase 2, 50 Not applicable, 34 Phase 4, 33 Phase 1.
Follow Retinal Vein Occlusion: new trials by email Literature Review of Retinal Vein Occlusion trials Research Report on Retinal Vein Occlusion
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Emerging Indications for Hyperbaric Oxygen Treatment Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis | Phase 4 | Not yet recruiting | Jay C. Buckey Jr. | 100 | 2026-11-01 | 2026-09-09 |
| Changes in Intraocular Pressure After Intravitreal Injection Diabetic Macular Edema, Neovascular Age-Related Macular Degeneration | Not yet recruiting | Assiut University | 50 | 2026-10-01 | 2026-09-17 | |
| Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: Pain, Procedure Time, Patient Satisfaction, and Safety Eyelid Speculum Retraction, Cotton-Tipped Applicator Retraction - Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema | Not applicable | Active not recruiting | Jakkrit Juhong | 129 | 2026-09-09 | 2026-09-25 |
| A Phase I Study of GenSci148 Intravitreal Injection for Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion GenSci148 Injection - Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME) | Phase 1 | Not yet recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 60 | 2026-09-01 | 2026-09-14 |
| A Study on the Combination of Tongluo Huayu Formula in Treating RVO of Phlegm-Stasis Intertwinement Type: Based on the Mechanism of Systemic Metabolic Regulation Mediated by Gut Microbiota Conbercept Ophthalmic Injection, Tongluo Huayu Formula, Laser Photocoagulation - Retinal Vein Occlusion | Not applicable | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 80 | 2026-06-01 | 2026-07-22 |
| AI vs. Physician for Anti-VEGF Decision-Making: An RCT QiLin-assisted, physician only, without QiLin assisted - DME, Retinal Vein Occlusion (RVO) | Not applicable | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 200 | 2026-05-25 | 2026-05-22 |
| Patient Comfort Following Intravitreal Injections Using Iheezo Versus Standard Anesthesia Iheezo, Lidocaine pledget - Macular Degeneration, Diabetic Retinopathy | Phase 4 | Completed | Retina Consultants of Delmarva | 50 | 2026-05-20 | 2026-08-21 |
| Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy SCD411 0.05mL (2mg) - Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion | Phase 2 | Completed | Sam Chun Dang Pharm. Co. Ltd. | 33 | 2026-05-13 | 2026-06-08 |
| Retinal Clinical Assessment With AI-derived Quantitative Information AI-derived retinal quantitative information-assisted reporting - no Obvious Abnormalities, Diabetic Retinopathy (DR) | Not yet recruiting | Beijing Tongren Hospital | 29 | 2026-04-15 | 2026-04-29 | |
| Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Sham Subconjunctival Injection, Proparacaine Hydrochloride Ophthalmic Solution 0.5% - Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD) | Phase 4 | Enrolling by invitation | Harrow Inc | 236 | 2026-03-31 | 2026-04-07 |
| DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information. anti-VEGF medication - Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO) | Recruiting | Bayer | 50000 | 2026-03-03 | 2026-06-22 | |
| AI-Assisted Detection of Posterior Segment Diseases: DR, AMD, RVO, and Glaucoma VUNO Med-Fundus AI - Diabetic Retinopathy, Age Related Macular Degeneration | Not applicable | Completed | Inje University | 10 | 2026-02-20 | 2026-06-23 |
| Wide Field OCTA in Ocular Diseases Age - Related Macular Degeneration (AMD), Diabetic Macular Edema | Not yet recruiting | IRCCS San Raffaele | 200 | 2026-01-01 | 2025-12-30 | |
| High-throughput Large-model-based AI-assisted Diagnosis Using OCT No intervention - Diabetic Retinopathy (DR), Retinal Vein Occlusion (RVO) | Not yet recruiting | Peking Union Medical College Hospital | 2000 | 2025-11-30 | 2025-11-25 | |
| Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion ANXV - Non-Proliferative Diabetic Retinopathy, Retinal Vein Occlusion | Phase 2 | Recruiting | Annexin Pharmaceuticals AB | 12 | 2025-11-07 | 2025-12-02 |
| Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium Fluorescein sodium and Zeiss FF450 fundus camera, MB-102 and Zeiss FF450 fundus camera, Fluorescein sodium and commercially available optical angiography imaging system - Retinopathy, Retinal Vein Occlusion | Early Phase 1 | Recruiting | MediBeacon | 10 | 2025-11-06 | 2026-02-04 |
| Serum Cholinesterases, Paraoxonase, and Cardiovascular Risk After Intravitreal Bevacizumab blood test - Diabete Mellitus, Retina Vein Occlusion | Recruiting | Ataturk University | 180 | 2025-11-03 | 2026-04-24 | |
| A Dose-masked Study of Intravitreal Remigromig (EYE103) in Participants With NVAMD or Macular Edema Following BRVO Remigromig, Aflibercept 2.0 mg - Neovascular Age-Related Macular Degeneration (NVAMD), Branch Retinal Vein Occlusion (BRVO) | Phase 2 | Recruiting | EyeBiotech Ltd. | 160 | 2025-09-12 | 2026-10-20 |
| Robotic RVO Trial: Robot-assisted Retinal Vein Cannulation in Patients With Retinal Vein Occlusions Surgery with Preceyes Robot plus NHS standard of care - Retinal Vein Occlusion (RVO) | Not applicable | Recruiting | University of Oxford | 40 | 2025-09-01 | 2026-10-21 |
| Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment Anti-VEGF drug, Mecobalamin 5 MG, Placebo - Retinal Vein Occlusion (RVO) | Phase 4 | Recruiting | First Affiliated Hospital of Chongqing Medical University | 120 | 2025-08-01 | 2026-02-27 |
Showing 20 of 274. Sign in to see all of them.
Macular Edema (113) · Macular Degeneration (56) · Diabetic Retinopathy (38) · Vision Disorders (17) · Retinal Diseases (15) · Choroidal Neovascularization (9) · Retinal Artery Occlusion (9) · Glaucoma (8) · Wet Macular Degeneration (8) · Eye Diseases (6) · Geographic Atrophy (6) · Uveitis (6) · Epiretinal Membrane (5) · Central Serous Chorioretinopathy (4)
Cardiovascular Diseases (274) · Embolism and Thrombosis (274) · Venous Thrombosis (274) · Vascular Diseases (273) · Thrombosis (272) · Eye Diseases (268) · Retinal Diseases (259) · Retinal Degeneration (150) · Macular Degeneration (95) · Endocrine System Diseases (39) · Diabetes Complications (38) · Diabetic Angiopathies (38) · Pathological Conditions, Signs and Symptoms (38) · Diabetes Mellitus (35) · Nervous System Diseases (27)
Ranibizumab (60) · aflibercept (34) · Dexamethasone (22) · Bevacizumab (20) · Calcium Dobesilate (18) · salicylhydroxamic acid (13) · Triamcinolone Acetonide (8) · faricimab (5) · Triamcinolone (4) · Lasers (3) · Tomography, Optical Coherence (3) · Vitrectomy (3) · brolucizumab (3) · pegaptanib (3) · KH902 fusion protein (2)
Novartis Pharmaceuticals (19) · Allergan (16) · Bayer (8) · National Eye Institute (NEI) (7) · Assiut University (4) · Clearside Biomedical, Inc. (4) · Hoffmann-La Roche (4) · Medical University of Vienna (4) · Shahid Beheshti University of Medical Sciences (4) · Barnes Retina Institute (3) · California Retina Consultants (3) · Chengdu Kanghong Biotech Co., Ltd. (3) · Genentech, Inc. (3) · Johns Hopkins University (3) · Peter A Campochiaro, MD (3)
United States (103) · China (35) · France (29) · Germany (24) · Canada (21) · United Kingdom (21) · Italy (20) · Spain (18) · Austria (17) · Japan (17) · Israel (15) · South Korea (15) · Australia (14) · Hungary (13) · Poland (13)
Peter A Campochiaro, MD (4) · Thomas Ciulla, MD (3) · Catherine A Cukras, M.D. (2) · Gaurav K Shah, MD (2) · Glenn J Jaffe, MD (2) · Jason Hsu, MD (2) · Lawrence A. Yannuzzi, MD (2) · Michael Gaynon, MD (2)
PMID 36912792, PMID 32633861, PMID 23415775, PMID 23699977, PMID 25677668, PMID 34934034, PMID 38280653, PMID 42753135, PMID 10372879, PMID 11297486, PMID 12941734, PMID 12967792, PMID 15715559, PMID 15992752, PMID 17188044, PMID 17353400, PMID 17621193, PMID 17675159, PMID 18054885, PMID 18173426, PMID 18189152, PMID 1850220, PMID 19052771, PMID 1922252, PMID 19268890, PMID 19365011, PMID 19365036, PMID 19477488, PMID 19584648, PMID 19592101, PMID 19752419, PMID 19752420, PMID 20110127, PMID 20212194, PMID 20212197, PMID 20591399, PMID 20702826, PMID 21051706, PMID 21149775, PMID 21467183, PMID 21764136, PMID 22264944, PMID 22464364, PMID 22559899, PMID 22657949, PMID 22801846, PMID 22960949, PMID 23006995, PMID 23049087, PMID 23229691
2018 (3), 2009 (2), 1UG1EY026876-01A1 (1), 1UG1EY028517-01 (1), 2014 (1), 2019 (1), R01EY030564 (1), U10EY014351 (1), U10EY014352 (1), U10EY014404 (1), U10EY023521 (1), U10EY023529 (1), U10EY023533 (1)